BidaskClub cut shares of Esperion Therapeutics (NASDAQ:ESPR) from a buy rating to a hold rating in a report released on Tuesday, March 20th.
Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC raised shares of Esperion Therapeutics from a buy rating to a strong-buy rating and increased their target price for the company from $72.00 to $81.00 in a research report on Thursday, December 14th. JPMorgan Chase reissued a neutral rating and set a $65.00 target price (up previously from $55.00) on shares of Esperion Therapeutics in a research report on Wednesday, February 21st. ValuEngine raised shares of Esperion Therapeutics from a sell rating to a hold rating in a research report on Friday, February 2nd. Deutsche Bank increased their target price on shares of Esperion Therapeutics to $100.00 and gave the company a buy rating in a research report on Friday, March 9th. Finally, Credit Suisse Group initiated coverage on shares of Esperion Therapeutics in a research report on Wednesday, January 17th. They set an outperform rating and a $103.00 target price for the company. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $92.54.
Shares of NASDAQ ESPR traded up $0.95 during midday trading on Tuesday, reaching $74.26. 760,029 shares of the company’s stock traded hands, compared to its average volume of 635,378. Esperion Therapeutics has a one year low of $30.95 and a one year high of $82.68. The company has a market cap of $1,847.26, a PE ratio of -10.62 and a beta of 2.51.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.80) by $0.36. During the same quarter in the prior year, the company earned ($1.29) EPS. equities research analysts expect that Esperion Therapeutics will post -5.61 earnings per share for the current year.
In other news, Director Roger S. Newton sold 25,000 shares of the stock in a transaction on Thursday, March 29th. The shares were sold at an average price of $72.37, for a total value of $1,809,250.00. Following the sale, the director now owns 639,682 shares in the company, valued at $46,293,786.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $71.79, for a total transaction of $838,076.46. Following the completion of the sale, the director now owns 3,177 shares in the company, valued at approximately $228,076.83. The disclosure for this sale can be found here. Company insiders own 32.50% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Esperion Therapeutics in the fourth quarter worth $222,000. BB&T Securities LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter worth $263,000. First Mercantile Trust Co. increased its stake in shares of Esperion Therapeutics by 56.0% in the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock worth $279,000 after acquiring an additional 1,519 shares during the period. Creative Planning acquired a new stake in shares of Esperion Therapeutics in the fourth quarter worth $314,000. Finally, Oakmont Partners LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter worth $323,000. Hedge funds and other institutional investors own 91.66% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Lowers Esperion Therapeutics (ESPR) to Hold” was originally reported by Macon Daily and is the property of of Macon Daily. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://macondaily.com/2018/04/12/esperion-therapeutics-espr-downgraded-to-hold-at-bidaskclub-updated-updated-updated.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.